John P. Kenny - 24 Jun 2022 Form 4 Insider Report for MERIDIAN BIOSCIENCE INC

Role: Chief Executive Officer, Director
Signature: /s/ Jeffery T. Pinkston as Attorney-in-fact for John P. Kenny
Issuer symbol: N/A
Transactions as of: 24 Jun 2022
Net transactions value: -$1,516,165
Form type: 4
Filing time: 28 Jun 2022, 09:42:43 UTC
Previous filing: 24 Jun 2022
Next filing: 05 Oct 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	VIVO	Common Stock	Options Exercise	$136,946	+13,559	+5.1%	$10.10	278,690	24 Jun 2022	Direct
transaction	VIVO	Common Stock	Sale	$406,836	-13,559	-4.9%	$30.00	265,131	24 Jun 2022	Direct	F1, F2
transaction	VIVO	Common Stock	Options Exercise	$620,514	+61,437	+23%	$10.10	326,568	27 Jun 2022	Direct
transaction	VIVO	Common Stock	Sale	$1,866,788	-61,437	-19%	$30.39	265,131	27 Jun 2022	Direct	F3, F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	VIVO	Stock Options (Right to Buy)	Options Exercise	$0	-13,559	-9.6%	$0.000000	127,476	24 Jun 2022	Common Stock	13,559	$10.10	Direct	F5, F6
transaction	VIVO	Stock Options (Right to Buy)	Options Exercise	$0	-61,437	-48%	$0.000000	66,039	27 Jun 2022	Common Stock	61,437	$10.10	Direct	F6, F7

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person effective November 15, 2021.
F2	The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $30.00 to $30.11. The Reporting Person undertakes to provide full pricing information if requested by the Securities and Exchange Commission, the issuer or a security holder of the issuer.
F3	The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person effective November 15, 2021.
F4	The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $30.00 to $30.76. The Reporting Person undertakes to provide full pricing information if requested by the Securities and Exchange Commission, the issuer or a security holder of the issuer.
F5	The option exercises reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person effective November 15, 2021.
F6	These non-qualified options were awarded under the 2012 Stock Incentive Plan pursuant to Mr. Kenny's Amended and Restated Employment Agreement effective October 1, 2019. The options vest on a pro rata basis over the three (3) years from the Agreement's effective date.
F7	The option exercises reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person effective November 15, 2021.